Heinrich Feldmann

List of Publications by Year in Descending Order

351 papers	22,354 citations	80 h-index	135 g-index
396 ext. papers	25,809 ext. citations	10.2 avg, IF	7.07 L-index

#	Paper	IF	Citations
351	SARS-CoV-2 reinfection prevents acute respiratory disease in Syrian hamsters but not replication in the upper respiratory tract.. *Cell Reports*, **2022**, 110515	10.6	1
350	SARS-CoV2 variant-specific replicating RNA vaccines protect from disease and pathology and reduce viral shedding following challenge with heterologous SARS-CoV2 variants of concern. **2021**,		1
349	UK B.1.1.7 (Alpha) variant exhibits increased respiratory replication and shedding in nonhuman primates. *Emerging Microbes and Infections*, **2021**, 10, 2173-2182	18.9	5
348	Reston virus causes severe respiratory disease in young domestic pigs. *Proceedings of the National Academy of Sciences of the United States of America*, **2021**, 118,	11.5	6
347	Targeting Ebola virus replication through pharmaceutical intervention. *Expert Opinion on Investigational Drugs*, **2021**, 30, 201-226	5.9	6
346	Has a Cellular Immune Response Profile Distinct from Laboratory Mice. *Viruses*, **2021**, 13,	6.2	1
345	Lassa Virus Treatment Options. *Microorganisms*, **2021**, 9,	4.9	7
344	Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model. *Nature Communications*, **2021**, 12, 2295	17.4	48
343	Recovery from acute SARS-CoV-2 infection and development of anamnestic immune responses in T cell-depleted rhesus macaques **2021**,		3
342	A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques. *Cell Reports Medicine*, **2021**, 2, 100230	18	40
341	Favipiravir (T-705) Protects IFNAR Mice against Lethal Zika Virus Infection in a Sex-Dependent Manner. *Microorganisms*, **2021**, 9,	4.9	1
340	Hematologic and serum biochemistry reference intervals using defined ASCVP methodology for laboratory natal multimammate mice (). *Laboratory Animals*, **2021**, 55, 417-427	2.6	0
339	An Intramuscular DNA Vaccine for SARS-CoV-2 Decreases Viral Lung Load but Not Lung Pathology in Syrian Hamsters. *Microorganisms*, **2021**, 9,	4.9	3
338	Intradermal delivery of a synthetic DNA vaccine protects macaques from Middle East respiratory syndrome coronavirus. *JCI Insight*, **2021**, 6,	9.9	3
337	UK B.1.1.7 variant exhibits increased respiratory replication and shedding in nonhuman primates **2021**,		4
336	Inactivation of SARS-CoV-2 Laboratory Specimens. *American Journal of Tropical Medicine and Hygiene*, **2021**,	3.2	14
335	Ebola Virus Glycoprotein Domains Associated with Protective Efficacy. *Vaccines*, **2021**, 9,	5.3	3

334	A DNA-based vaccine protects against Crimean-Congo haemorrhagic fever virus disease in a Cynomolgus macaque model. *Nature Microbiology*, **2021**, 6, 187-195	26.6	12
333	Inhibition of SARS-CoV-2 in Vero cell cultures by peptide-conjugated morpholino oligomers. *Journal of Antimicrobial Chemotherapy*, **2021**, 76, 413-417	5.1	9
332	T-Cells and Interferon Gamma Are Necessary for Survival Following Crimean-Congo Hemorrhagic Fever Virus Infection in Mice. *Microorganisms*, **2021**, 9,	4.9	3
331	Immunocompetent mouse model for Crimean-Congo hemorrhagic fever virus. *ELife*, **2021**, 10,	8.9	8
330	A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques **2021**,		5
329	Purification of Crimean-Congo hemorrhagic fever virus nucleoprotein and its utility for serological diagnosis. *Scientific Reports*, **2021**, 11, 2324	4.9	1
328	A Look into Genomes: Functions of Non-Structural (NS) Proteins. *Viruses*, **2021**, 13,	6.2	8
327	Establishment of a Genetically Confirmed Breeding Colony of from Wild-Caught Founders from West Africa. *Viruses*, **2021**, 13,	6.2	5
326	Recovery from Acute SARS-CoV-2 Infection and Development of Anamnestic Immune Responses in T Cell-Depleted Rhesus Macaques. *MBio*, **2021**, 12, e0150321	7.8	12
325	The Ebola virus soluble glycoprotein contributes to viral pathogenesis by activating the MAP kinase signaling pathway. *PLoS Pathogens*, **2021**, 17, e1009937	7.6	0
324	Therapeutic Efficacy of Human Monoclonal Antibodies against Andes Virus Infection in Syrian Hamsters. *Emerging Infectious Diseases*, **2021**, 27, 2707-2710	10.2	1
323	Alkhurma haemorrhagic fever virus causes lethal disease in IFNAR mice. *Emerging Microbes and Infections*, **2021**, 10, 1077-1087	18.9	1
322	High dose of vesicular stomatitis virus-vectored Ebola virus vaccine causes vesicular disease in swine without horizontal transmission. *Emerging Microbes and Infections*, **2021**, 10, 651-663	18.9	0
321	Single-cell RNA sequencing reveals SARS-CoV-2 infection dynamics in lungs of African green monkeys. *Science Translational Medicine*, **2021**, 13,	17.5	68
320	Histologic pulmonary lesions of SARS-CoV-2 in 4 nonhuman primate species: An institutional comparative review.. *Veterinary Pathology*, **2021**, 3009858211067468	2.8	2
319	A live-attenuated viral vector vaccine protects mice against lethal challenge with Kyasanur Forest disease virus.. *Npj Vaccines*, **2021**, 6, 152	9.5	0
318	Defining the Syrian hamster as a highly susceptible preclinical model for SARS-CoV-2 infection. *Emerging Microbes and Infections*, **2020**, 9, 2673-2684	18.9	91
317	Ebola. *New England Journal of Medicine*, **2020**, 382, 1832-1842	59.2	49

316	Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. *Proceedings of the National Academy of Sciences of the United States of America* , **2020**, 117, 6771-6776	11.5	587
315	Isolate from Blood of Fatal Ebola Virus Disease Case. *Pathogens*, **2020**, 9,	4.5	1
314	Efficacy of favipiravir (T-705) against Crimean-Congo hemorrhagic fever virus infection in cynomolgus macaques. *Antiviral Research*, **2020**, 181, 104858	10.8	10
313	Transcriptional Correlates of Tolerance and Lethality in Mice Predict Ebola Virus Disease Patient Outcomes. *Cell Reports*, **2020**, 30, 1702-1713.e6	10.6	9
312	A single dose of a vesicular stomatitis virus-based influenza vaccine confers rapid protection against H5 viruses from different clades. *Npj Vaccines*, **2020**, 5, 4	9.5	28
311	Niemann-Pick C1 Heterogeneity of Bat Cells Controls Filovirus Tropism. *Cell Reports*, **2020**, 30, 308-319.e5	10.6	10
310	Utility of primary cells to examine NPC1 receptor expression in Mops condylurus, a potential Ebola virus reservoir. *PLoS Neglected Tropical Diseases*, **2020**, 14, e0007952	4.8	4
309	Neutralizing Monoclonal Antibodies against the Gn and the Gc of the Andes Virus Glycoprotein Spike Complex Protect from Virus Challenge in a Preclinical Hamster Model. *MBio*, **2020**, 11,	7.8	16
308	Hydroxychloroquine prophylaxis and treatment is ineffective in macaque and hamster SARS-CoV-2 disease models. *JCI Insight*, **2020**, 5,	9.9	20
307	Quadrivalent VesiculoVax vaccine protects nonhuman primates from viral-induced hemorrhagic fever and death. *Journal of Clinical Investigation*, **2020**, 130, 539-551	15.9	13
306	Methanol Fixation, but not Giemsa Staining, Inactivates Ebola and Lassa Viruses in Peripheral Blood Smears Made on Plastic Microscope Slides. *American Journal of Tropical Medicine and Hygiene*, **2020**, 103, 2085-2090	3.2	
305	Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model **2020**,		6
304	Evaluation of drugs for potential repurposing against COVID-19 using a tier-based scoring system. *Antiviral Therapy*, **2020**, 25, 223-231	1.6	6
303	Single-dose replicating RNA vaccine induces neutralizing antibodies against SARS-CoV-2 in nonhuman primates **2020**,		17
302	Hydroxychloroquine Proves Ineffective in Hamsters and Macaques Infected with SARS-CoV-2 **2020**,		16
301	SARS-CoV-2 infection dynamics in lungs of African green monkeys **2020**,		8
300	Defining the Syrian hamster as a highly susceptible preclinical model for SARS-CoV-2 infection **2020** ,		13
299	Kyasanur Forest Disease and Alkhurma Hemorrhagic Fever Virus-Two Neglected Zoonotic Pathogens. *Microorganisms*, **2020**, 8,	4.9	6

298	Susceptibility of swine cells and domestic pigs to SARS-CoV-2. *Emerging Microbes and Infections*, **2020**, 9, 2278-2288	18.9	51
297	An -derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates. *Science Translational Medicine*, **2020**, 12,	17.5	96
296	Prior vaccination with rVSV-ZEBOV does not interfere with but improves efficacy of postexposure antibody treatment. *Nature Communications*, **2020**, 11, 3736	17.4	8
295	Characterization of a novel STAT 2 knock-out hamster model of Crimean-Congo hemorrhagic fever virus pathogenesis. *Scientific Reports*, **2020**, 10, 12378	4.9	5
294	A biaryl sulfonamide derivative as a novel inhibitor of filovirus infection. *Antiviral Research*, **2020**, 183, 104932	10.8	0
293	Multiple DNA viruses identified in multimammate mouse (Mastomys natalensis) populations from across regions of sub-Saharan Africa. *Archives of Virology*, **2020**, 165, 2291-2299	2.6	1
292	Emerging preclinical evidence does not support broad use of hydroxychloroquine in COVID-19 patients. *Nature Communications*, **2020**, 11, 4253	17.4	24
291	Dendritic Cells Generated From , a Likely Filovirus Reservoir Host, Are Susceptible to and Activated by Zaire Ebolavirus Infection. *Frontiers in Immunology*, **2019**, 10, 2414	8.4	1
290	Animal models for Lassa virus infection. *Current Opinion in Virology*, **2019**, 37, 112-117	7.5	5
289	Prophylactic efficacy of a human monoclonal antibody against MERS-CoV in the common marmoset. *Antiviral Research*, **2019**, 163, 70-74	10.8	8
288	Remdesivir (GS-5734) protects African green monkeys from Nipah virus challenge. *Science Translational Medicine*, **2019**, 11,	17.5	108
287	Antiviral Innate Responses Induced by VSV-EBOV Vaccination Contribute to Rapid Protection. *MBio*, **2019**, 10,	7.8	19
286	Differential Innate Immune Responses Elicited by Nipah Virus and Cedar Virus Correlate with Disparate In Vivo Pathogenesis in Hamsters. *Viruses*, **2019**, 11,	6.2	18
285	Crimean-Congo Hemorrhagic Fever Mouse Model Recapitulating Human Convalescence. *Journal of Virology*, **2019**, 93,	6.6	12
284	Recombinant subunit vaccines protect guinea pigs from lethal Ebola virus challenge. *Vaccine*, **2019**, 37, 6942-6950	4.1	7
283	Therapeutic strategies to target the Ebola virus life cycle. *Nature Reviews Microbiology*, **2019**, 17, 593-606	22.2	72
282	Single low-dose VSV-EBOV vaccination protects cynomolgus macaques from lethal Ebola challenge. *EBioMedicine*, **2019**, 49, 223-231	8.8	17
281	Impact of intensive care unit supportive care on the physiology of Ebola virus disease in a universally lethal non-human primate model. *Intensive Care Medicine Experimental*, **2019**, 7, 54	3.7	3

280	Gamma Irradiation as an Effective Method for Inactivation of Emerging Viral Pathogens. *American Journal of Tropical Medicine and Hygiene*, **2019**, 100, 1275-1277	3.2	64
279	Host Competency of the Multimammate Rat Demonstrated by Prolonged Spirochetemias with the African Relapsing Fever Spirochete. *American Journal of Tropical Medicine and Hygiene*, **2019**, 101, 1272-1275	3.2	4
278	Ebola vaccine trials: progress in vaccine safety and immunogenicity. *Expert Review of Vaccines*, **2019**, 18, 1229-1242	5.2	41
277	Oseltamivir Is Effective against 1918 Influenza Virus Infection of Macaques but Vulnerable to Escape. *MBio*, **2019**, 10,	7.8	2
276	Protection Against Marburg Virus Using a Recombinant VSV-Vaccine Depends on T and B Cell Activation. *Frontiers in Immunology*, **2018**, 9, 3071	8.4	15
275	A cynomolgus macaque model for Crimean-Congo haemorrhagic fever. *Nature Microbiology*, **2018**, 3, 556-562	26.6	38
274	Differential Ability of Pandemic and Seasonal H1N1 Influenza A Viruses To Alter the Function of Human Neutrophils. *MSphere*, **2018**, 3,	5	9
273	Post-exposure treatments for Ebola and Marburg virus infections. *Nature Reviews Drug Discovery*, **2018**, 17, 413-434	64.1	72
272	A Single Dose of Modified Vaccinia Ankara expressing Ebola Virus Like Particles Protects Nonhuman Primates from Lethal Ebola Virus Challenge. *Scientific Reports*, **2018**, 8, 864	4.9	33
271	1918 H1N1 Influenza Virus Replicates and Induces Proinflammatory Cytokine Responses in Extrarespiratory Tissues of Ferrets. *Journal of Infectious Diseases*, **2018**, 217, 1237-1246	7	36
270	Filoviruses: Ecology, Molecular Biology, and Evolution. *Advances in Virus Research*, **2018**, 100, 189-221	10.7	40
269	Transmission of henipaviruses. *Current Opinion in Virology*, **2018**, 28, 7-11	7.5	24
268	Human Polyclonal Antibodies Produced by Transchromosomal Cattle Provide Partial Protection Against Lethal Zaire Ebolavirus Challenge in Rhesus Macaques. *Journal of Infectious Diseases*, **2018**, 218, S658-S661	7	4
267	Lifecycle modelling systems support inosine monophosphate dehydrogenase (IMPDH) as a pro-viral factor and antiviral target for New World arenaviruses. *Antiviral Research*, **2018**, 157, 140-150	10.8	11
266	A VSV-based Zika virus vaccine protects mice from lethal challenge. *Scientific Reports*, **2018**, 8, 11043	4.9	46
265	Lethal Zika Virus Disease Models in Young and Older Interferon ⍺/β Receptor Knock Out Mice. *Frontiers in Cellular and Infection Microbiology*, **2018**, 8, 117	5.9	18
264	Pathogenicity and Viral Shedding of MERS-CoV in Immunocompromised Rhesus Macaques. *Frontiers in Immunology*, **2018**, 9, 205	8.4	34
263	Monoclonal Antibody Cocktail Protects Hamsters From Lethal Marburg Virus Infection. *Journal of Infectious Diseases*, **2018**, 218, S662-S665	7	6

262	Single-Nucleotide Polymorphisms in Human NPC1 Influence Filovirus Entry Into Cells. *Journal of Infectious Diseases*, **2018**, 218, S397-S402	7	12
261	A genome-wide siRNA screen identifies a druggable host pathway essential for the Ebola virus life cycle. *Genome Medicine*, **2018**, 10, 58	14.4	29
260	Pathogenicity of Ebola and Marburg Viruses Is Associated With Differential Activation of the Myeloid Compartment in Humanized Triple Knockout-Bone Marrow, Liver, and Thymus Mice. *Journal of Infectious Diseases*, **2018**, 218, S409-S417	7	10
259	Tip Your Cap for Ebola Virus Neutralization. *Immunity*, **2018**, 49, 204-206	32.3	
258	Ebola Virus Infection in Commonly Used Laboratory Mouse Strains. *Journal of Infectious Diseases*, **2018**, 218, S453-S457	7	10
257	Prophylactic and therapeutic efficacy of mAb treatment against MERS-CoV in common marmosets. *Antiviral Research*, **2018**, 156, 64-71	10.8	23
256	The Effect of Plasmodium on the Outcome of Ebola Virus Infection in a Mouse Model. *Journal of Infectious Diseases*, **2018**, 218, S434-S437	7	2
255	Recently Identified Mutations in the Ebola Virus-Makona Genome Do Not Alter Pathogenicity in Animal Models. *Cell Reports*, **2018**, 23, 1806-1816	10.6	35
254	Recent advances in understanding Crimean-Congo hemorrhagic fever virus. *F1000Research*, **2018**, 7,	3.6	37
253	Two recombinant human monoclonal antibodies that protect against lethal Andes hantavirus infection in vivo. *Science Translational Medicine*, **2018**, 10,	17.5	26
252	Nucleocapsid protein-based vaccine provides protection in mice against lethal Crimean-Congo hemorrhagic fever virus challenge. *PLoS Neglected Tropical Diseases*, **2018**, 12, e0006628	4.8	28
251	Distinct Biological Phenotypes of Marburg and Ravn Virus Infection in Macaques. *Journal of Infectious Diseases*, **2018**, 218, S458-S465	7	4
250	Use of Favipiravir to Treat Lassa Virus Infection in Macaques. *Emerging Infectious Diseases*, **2018**, 24, 1696-1699	10.2	47
249	Ebola: Lessons on Vaccine Development. *Annual Review of Microbiology*, **2018**, 72, 423-446	17.5	31
248	The vesicular stomatitis virus-based Ebola virus vaccine: From concept to clinical trials. *Human Vaccines and Immunotherapeutics*, **2018**, 14, 2107-2113	4.4	68
247	Favipiravir (T-705) but not ribavirin is effective against two distinct strains of Crimean-Congo hemorrhagic fever virus in mice. *Antiviral Research*, **2018**, 157, 18-26	10.8	29
246	Immunobiology of Ebola and Lassa virus infections. *Nature Reviews Immunology*, **2017**, 17, 195-207	36.5	68
245	Transcriptomic analysis reveals a previously unknown role for CD8 T-cells in rVSV-EBOV mediated protection. *Scientific Reports*, **2017**, 7, 919	4.9	19

244	Reverse Genetics Systems for Filoviruses. *Methods in Molecular Biology*, **2017**, 1602, 159-170	1.4	5
243	Efficacy of antibody-based therapies against Middle East respiratory syndrome coronavirus (MERS-CoV) in common marmosets. *Antiviral Research*, **2017**, 143, 30-37	10.8	50
242	Dromedary camels in northern Mali have high seropositivity to MERS-CoV. *One Health*, **2017**, 3, 41-43	7.6	31
241	Reply to Colebunders. *Clinical Infectious Diseases*, **2017**, 64, 232	11.6	
240	The Pathogenesis of Ebola Virus Disease. *Annual Review of Pathology: Mechanisms of Disease*, **2017**, 12, 387-418	34	164
239	Serosurvey of Crimean-Congo Hemorrhagic Fever Virus in Cattle, Mali, West Africa. *American Journal of Tropical Medicine and Hygiene*, **2017**, 96, 1341-1345	3.2	13
238	Domestic Pig Unlikely Reservoir for MERS-CoV. *Emerging Infectious Diseases*, **2017**, 23, 985-988	10.2	17
237	Severity of Disease in Humanized Mice Infected With Ebola Virus or Reston Virus Is Associated With Magnitude of Early Viral Replication in Liver. *Journal of Infectious Diseases*, **2017**, 217, 58-63	7	19
236	Human immune system mouse models of Ebola virus infection. *Current Opinion in Virology*, **2017**, 25, 90-96	7.5	14
235	Amending Koch's postulates for viral disease: When "growth in pure culture" leads to a loss of virulence. *Antiviral Research*, **2017**, 137, 1-5	10.8	12
234	The Crux of Ebola Diagnostics. *Journal of Infectious Diseases*, **2017**, 216, 1340-1342	7	7
233	Ebolavirus: An Overview of Molecular and Clinical Pathogenesis. *Methods in Molecular Biology*, **2017**, 1628, 39-50	1.4	5
232	Escape From Monoclonal Antibody Neutralization Affects Henipavirus Fitness In Vitro and In Vivo. *Journal of Infectious Diseases*, **2016**, 213, 448-55	7	5
231	Response to Comment on "Mutation rate and genotype variation of Ebola virus from Mali case sequences". *Science*, **2016**, 353, 658	33.3	3
230	Plasmodium Parasitemia Associated With Increased Survival in Ebola Virus-Infected Patients. *Clinical Infectious Diseases*, **2016**, 63, 1026-33	11.6	37
229	Discovery of an antibody for pan-ebolavirus therapy. *Scientific Reports*, **2016**, 6, 20514	4.9	66
228	Cytomegalovirus-based vaccine expressing Ebola virus glycoprotein protects nonhuman primates from Ebola virus infection. *Scientific Reports*, **2016**, 6, 21674	4.9	47
227	Ebola virus is unlikely to become endemic in West Africa. *Nature Microbiology*, **2016**, 1, 16007	26.6	3

226	Ebola Laboratory Response at the Eternal Love Winning Africa Campus, Monrovia, Liberia, 2014-2015. *Journal of Infectious Diseases*, **2016**, 214, S169-S176	7	17
225	Laguna Negra Virus Infection Causes Hantavirus Pulmonary Syndrome in Turkish Hamsters (Mesocricetus brandti). *Veterinary Pathology*, **2016**, 53, 182-9	2.8	9
224	A Comparative Review of Animal Models of Middle East Respiratory Syndrome Coronavirus Infection. *Veterinary Pathology*, **2016**, 53, 521-31	2.8	26
223	An Acute Immune Response to Middle East Respiratory Syndrome Coronavirus Replication Contributes to Viral Pathogenicity. *American Journal of Pathology*, **2016**, 186, 630-8	5.8	32
222	Fc□eceptor IIa-mediated Src Signaling Pathway Is Essential for the Antibody-Dependent Enhancement of Ebola Virus Infection. *PLoS Pathogens*, **2016**, 12, e1006139	7.6	22
221	Effective Chemical Inactivation of Ebola Virus. *Emerging Infectious Diseases*, **2016**, 22, 1292-4	10.2	53
220	Lassa Virus Seroprevalence in Sibirilia Commune, Bougouni District, Southern Mali. *Emerging Infectious Diseases*, **2016**, 22, 657-63	10.2	21
219	Nanopore Sequencing as a Rapidly Deployable Ebola Outbreak Tool. *Emerging Infectious Diseases*, **2016**, 22, 331-4	10.2	130
218	Identifying Early Target Cells of Nipah Virus Infection in Syrian Hamsters. *PLoS Neglected Tropical Diseases*, **2016**, 10, e0005120	4.8	11
217	A hamster model for Marburg virus infection accurately recapitulates Marburg hemorrhagic fever. *Scientific Reports*, **2016**, 6, 39214	4.9	20
216	Peri-exposure protection against Nipah virus disease using a single-dose recombinant vesicular stomatitis virus-based vaccine. *Npj Vaccines*, **2016**, 1,	9.5	13
215	Ebola virus vaccines - reality or fiction?. *Expert Review of Vaccines*, **2016**, 15, 1421-1430	5.2	26
214	Ebola Virus Replication and Disease Without Immunopathology in Mice Expressing Transgenes to Support Human Myeloid and Lymphoid Cell Engraftment. *Journal of Infectious Diseases*, **2016**, 214, S308-S318	7	19
213	Clinical Chemistry of Patients With Ebola in Monrovia, Liberia. *Journal of Infectious Diseases*, **2016**, 214, S303-S307	7	7
212	Development of an Immunochromatography Assay (QuickNavi-Ebola) to Detect Multiple Species of Ebolaviruses. *Journal of Infectious Diseases*, **2016**, 214, S185-S191	7	14
211	Efficacy of Vesicular Stomatitis Virus-Ebola Virus Postexposure Treatment in Rhesus Macaques Infected With Ebola Virus Makona. *Journal of Infectious Diseases*, **2016**, 214, S360-S366	7	42
210	Virology. Delineating Ebola entry. *Science*, **2015**, 347, 947-8	33.3	10
209	Vaccination With a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge With a Lethal Dose of Ebola Virus. *Journal of Infectious Diseases*, **2015**, 212 Suppl 2, S443-51	7	37

208	Considerations in the Use of Nonhuman Primate Models of Ebola Virus and Marburg Virus Infection. *Journal of Infectious Diseases*, **2015**, 212 Suppl 2, S91-7	7	84
207	A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses. *PLoS Neglected Tropical Diseases*, **2015**, 9, e0003736	4.8	80
206	Vaccines. An Ebola whole-virus vaccine is protective in nonhuman primates. *Science*, **2015**, 348, 439-42	33.3	61
205	Interaction between TIM-1 and NPC1 Is Important for Cellular Entry of Ebola Virus. *Journal of Virology*, **2015**, 89, 6481-93	6.6	51
204	Immune Response to Marburg Virus Angola Infection in Nonhuman Primates. *Journal of Infectious Diseases*, **2015**, 212 Suppl 2, S234-41	7	23
203	Personal Protective Equipment for Filovirus Epidemics: A Call for Better Evidence. *Journal of Infectious Diseases*, **2015**, 212 Suppl 2, S98-S100	7	31
202	Next-generation sequencing reveals a controlled immune response to Zaire Ebola virus challenge in cynomolgus macaques immunized with vesicular stomatitis virus expressing Zaire Ebola virus glycoprotein (VSV□/EBOVgp). *Vaccine Journal*, **2015**, 22, 354-6		19
201	Seroepidemiological Prevalence of Multiple Species of Filoviruses in Fruit Bats (Eidolon helvum) Migrating in Africa. *Journal of Infectious Diseases*, **2015**, 212 Suppl 2, S101-8	7	72
200	A cytomegalovirus-based vaccine provides long-lasting protection against lethal Ebola virus challenge after a single dose. *Vaccine*, **2015**, 33, 2261-2266	4.1	40
199	Single-dose live-attenuated vesicular stomatitis virus-based vaccine protects African green monkeys from Nipah virus disease. *Vaccine*, **2015**, 33, 2823-9	4.1	38
198	Virology. Mutation rate and genotype variation of Ebola virus from Mali case sequences. *Science*, **2015**, 348, 117-9	33.3	106
197	Safety of recombinant VSV-Ebola virus vaccine vector in pigs. *Emerging Infectious Diseases*, **2015**, 21, 702-4	10.2	19
196	Lack of protection against ebola virus from chloroquine in mice and hamsters. *Emerging Infectious Diseases*, **2015**, 21, 1065-7	10.2	47
195	EBOLA VACCINE. VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain. *Science*, **2015**, 349, 739-42	33.3	148
194	Stat1-Deficient Mice Are Not an Appropriate Model for Efficacy Testing of Recombinant Vesicular Stomatitis Virus-Based Filovirus Vaccines. *Journal of Infectious Diseases*, **2015**, 212 Suppl 2, S404-9	7	18
193	Importin-□ Is Involved in the Formation of Ebola Virus Inclusion Bodies but Is Not Essential for Pathogenicity in Mice. *Journal of Infectious Diseases*, **2015**, 212 Suppl 2, S316-21	7	8
192	Assessing the contribution of interferon antagonism to the virulence of West African Ebola viruses. *Nature Communications*, **2015**, 6, 8000	17.4	18
191	Suppressor of Cytokine Signaling 3 Is an Inducible Host Factor That Regulates Virus Egress during Ebola Virus Infection. *Journal of Virology*, **2015**, 89, 10399-406	6.6	29

190	A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates. *Science Translational Medicine*, **2015**, 7, 301ra132	17.5	182
189	Recent advances in research on Crimean-Congo hemorrhagic fever. *Journal of Clinical Virology*, **2015**, 64, 137-43	14.5	50
188	Delayed inflammatory and cell death responses are associated with reduced pathogenicity in Lujo virus-infected cynomolgus macaques. *Journal of Virology*, **2015**, 89, 2543-52	6.6	7
187	Rhabdovirus-based vaccine platforms against henipaviruses. *Journal of Virology*, **2015**, 89, 144-54	6.6	48
186	The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset. *Scientific Reports*, **2015**, 5, 14775	4.9	69
185	Delayed Disease Progression in Cynomolgus Macaques Infected with Ebola Virus Makona Strain. *Emerging Infectious Diseases*, **2015**, 21, 1777-83	10.2	64
184	Development and Characterization of Broadly Cross-reactive Monoclonal Antibodies Against All Known Ebolavirus Species. *Journal of Infectious Diseases*, **2015**, 212 Suppl 2, S410-3	7	12
183	Natural Immunity to Ebola Virus in the Syrian Hamster Requires Antibody Responses. *Journal of Infectious Diseases*, **2015**, 212 Suppl 2, S271-6	7	10
182	Characterization of a Bivalent Vaccine Capable of Inducing Protection Against Both Ebola and Cross-clade H5N1 Influenza in Mice. *Journal of Infectious Diseases*, **2015**, 212 Suppl 2, S435-42	7	9
181	Syrian hamsters (Mesocricetus auratus) oronasally inoculated with a Nipah virus isolate from Bangladesh or Malaysia develop similar respiratory tract lesions. *Veterinary Pathology*, **2015**, 52, 38-45	2.8	25
180	Emergency postexposure vaccination with vesicular stomatitis virus-vectored Ebola vaccine after needlestick. *JAMA - Journal of the American Medical Association*, **2015**, 313, 1249-55	27.4	66
179	Soluble Glycoprotein Is Not Required for Ebola Virus Virulence in Guinea Pigs. *Journal of Infectious Diseases*, **2015**, 212 Suppl 2, S242-6	7	13
178	Loss of Interleukin 1 Receptor Antagonist Enhances Susceptibility to Ebola Virus Infection. *Journal of Infectious Diseases*, **2015**, 212 Suppl 2, S329-35	7	11
177	Birth and pathogenesis of rogue respiratory viruses. *Annual Review of Pathology: Mechanisms of Disease*, **2015**, 10, 449-71	34	2
176	Ebola and Marburg haemorrhagic fever. *Journal of Clinical Virology*, **2015**, 64, 111-9	14.5	94
175	Vesicular stomatitis virus-based vaccines against Lassa and Ebola viruses. *Emerging Infectious Diseases*, **2015**, 21, 305-7	10.2	50
174	Differential lymphocyte and antibody responses in deer mice infected with Sin Nombre hantavirus or Andes hantavirus. *Journal of Virology*, **2014**, 88, 8319-31	6.6	18
173	Ebola Conquers West Africa - More to Come?. *EBioMedicine*, **2014**, 1, 2-3	8.8	1

172	Host genetic diversity enables Ebola hemorrhagic fever pathogenesis and resistance. *Science*, **2014**, 346, 987-91	33.3	183
171	A novel life cycle modeling system for Ebola virus shows a genome length-dependent role of VP24 in virus infectivity. *Journal of Virology*, **2014**, 88, 10511-24	6.6	102
170	Lymphopenia associated with highly virulent H5N1 virus infection due to plasmacytoid dendritic cell-mediated apoptosis of T cells. *Journal of Immunology*, **2014**, 192, 5906-12	5.3	41
169	Ebola virus vaccines: an overview of current approaches. *Expert Review of Vaccines*, **2014**, 13, 521-31	5.2	100
168	Ebola--a growing threat?. *New England Journal of Medicine*, **2014**, 371, 1375-8	59.2	65
167	Pathophysiology of hantavirus pulmonary syndrome in rhesus macaques. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 7114-9	11.5	47
166	Possible leap ahead in filovirus therapeutics. *Cell Research*, **2014**, 24, 647-8	24.7	12
165	African green monkeys recapitulate the clinical experience with replication of live attenuated pandemic influenza virus vaccine candidates. *Journal of Virology*, **2014**, 88, 8139-52	6.6	27
164	Single-dose live-attenuated Nipah virus vaccines confer complete protection by eliciting antibodies directed against surface glycoproteins. *Vaccine*, **2014**, 32, 2637-44	4.1	50
163	Ebola virus modulates transforming growth factor signaling and cellular markers of mesenchyme-like transition in hepatocytes. *Journal of Virology*, **2014**, 88, 9877-92	6.6	37
162	Novel neutralizing monoclonal antibodies protect rodents against lethal filovirus challenges. *Trials in Vaccinology*, **2014**, 3, 89-94		7
161	Modeling the lifecycle of Ebola virus under biosafety level 2 conditions with virus-like particles containing tetracistronic minigenomes. *Journal of Visualized Experiments*, **2014**, 52381	1.6	27
160	Durability of a vesicular stomatitis virus-based marburg virus vaccine in nonhuman primates. *PLoS ONE*, **2014**, 9, e94355	3.7	48
159	Sequencing, annotation and analysis of the Syrian hamster (Mesocricetus auratus) transcriptome. *PLoS ONE*, **2014**, 9, e112617	3.7	19
158	Reverse genetics systems as tools for the development of novel therapies against filoviruses. *Expert Review of Anti-Infective Therapy*, **2014**, 12, 1253-63	5.5	30
157	Infection with MERS-CoV causes lethal pneumonia in the common marmoset. *PLoS Pathogens*, **2014**, 10, e1004250	7.6	170
156	Foodborne transmission of nipah virus in Syrian hamsters. *PLoS Pathogens*, **2014**, 10, e1004001	7.6	40
155	Long-term single-dose efficacy of a vesicular stomatitis virus-based Andes virus vaccine in Syrian hamsters. *Viruses*, **2014**, 6, 516-23	6.2	16

154	Complete genome sequences of three ebola virus isolates from the 2014 outbreak in west Africa. *Genome Announcements*, **2014**, 2,		25
153	Therapeutic treatment of Nipah virus infection in nonhuman primates with a neutralizing human monoclonal antibody. *Science Translational Medicine*, **2014**, 6, 242ra82	17.5	87
152	Ebolavirus in West Africa, and the use of experimental therapies or vaccines. *BMC Biology*, **2014**, 12, 80	7.3	17
151	Vaccines for viral hemorrhagic fevers--progress and shortcomings. *Current Opinion in Virology*, **2013**, 3, 343-51	7.5	44
150	A novel Ebola virus expressing luciferase allows for rapid and quantitative testing of antivirals. *Antiviral Research*, **2013**, 99, 207-13	10.8	45
149	Expression profiling of lymph node cells from deer mice infected with Andes virus. *BMC Immunology*, **2013**, 14, 18	3.7	17
148	Treatment with interferon-2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. *Nature Medicine*, **2013**, 19, 1313-7	50.5	357
147	Animal models for highly pathogenic emerging viruses. *Current Opinion in Virology*, **2013**, 3, 205-9	7.5	31
146	Novel mutations in Marburg virus glycoprotein associated with viral evasion from antibody mediated immune pressure. *Journal of General Virology*, **2013**, 94, 876-883	4.9	13
145	The adaptive immune response does not influence hantavirus disease or persistence in the Syrian hamster. *Immunology*, **2013**, 140, 168-78	7.8	40
144	A Syrian golden hamster model recapitulating ebola hemorrhagic fever. *Journal of Infectious Diseases*, **2013**, 207, 306-18	7	92
143	Lethal Crimean-Congo hemorrhagic fever virus infection in interferon -receptor knockout mice is associated with high viral loads, proinflammatory responses, and coagulopathy. *Journal of Infectious Diseases*, **2013**, 207, 1909-21	7	74
142	Vesicular stomatitis virus-based vaccines protect nonhuman primates against Bundibugyo ebolavirus. *PLoS Neglected Tropical Diseases*, **2013**, 7, e2600	4.8	67
141	Myxomavirus-derived serpin prolongs survival and reduces inflammation and hemorrhage in an unrelated lethal mouse viral infection. *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 4114-27	5.9	33
140	Geographic distribution and genetic characterization of Lassa virus in sub-Saharan Mali. *PLoS Neglected Tropical Diseases*, **2013**, 7, e2582	4.8	38
139	Ebola virus RNA editing depends on the primary editing site sequence and an upstream secondary structure. *PLoS Pathogens*, **2013**, 9, e1003677	7.6	40
138	Comparison of the pathogenicity of Nipah virus isolates from Bangladesh and Malaysia in the Syrian hamster. *PLoS Neglected Tropical Diseases*, **2013**, 7, e2024	4.8	46
137	An upstream open reading frame modulates ebola virus polymerase translation and virus replication. *PLoS Pathogens*, **2013**, 9, e1003147	7.6	53

136	A recently isolated Lassa virus from Mali demonstrates atypical clinical disease manifestations and decreased virulence in cynomolgus macaques. *Journal of Infectious Diseases*, **2013**, 207, 1316-27	7	39
135	Hamster-adapted Sin Nombre virus causes disseminated infection and efficiently replicates in pulmonary endothelial cells without signs of disease. *Journal of Virology*, **2013**, 87, 4778-82	6.6	26
134	Pneumonia from human coronavirus in a macaque model. *New England Journal of Medicine*, **2013**, 368, 1560-2	59.2	121
133	Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 16598-603	11.5	232
132	Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 1893-8	11.5	187
131	Seasonal H3N2 influenza A virus fails to enhance Staphylococcus aureus co-infection in a non-human primate respiratory tract infection model. *Virulence*, **2013**, 4, 707-15	4.7	20
130	Animal models of tick-borne hemorrhagic Fever viruses. *Pathogens*, **2013**, 2, 402-21	4.5	11
129	Ebola: facing a new transboundary animal disease?. *Developments in Biologicals*, **2013**, 135, 201-9		4
128	The Middle East respiratory syndrome coronavirus (MERS-CoV) does not replicate in Syrian hamsters. *PLoS ONE*, **2013**, 8, e69127	3.7	105
127	Viral hemorrhagic fevers: advancing the level of treatment. *BMC Medicine*, **2012**, 10, 31	11.4	28
126	Lassa fever in West Africa: evidence for an expanded region of endemicity. *Zoonoses and Public Health*, **2012**, 59 Suppl 2, 43-7	2.9	71
125	Flexibility of mobile laboratory unit in support of patient management during the 2007 Ebola-Zaire outbreak in the Democratic Republic of Congo. *Zoonoses and Public Health*, **2012**, 59 Suppl 2, 151-7	2.9	29
124	Immune parameters correlate with protection against ebola virus infection in rodents and nonhuman primates. *Science Translational Medicine*, **2012**, 4, 158ra146	17.5	117
123	The immune response to Nipah virus infection. *Archives of Virology*, **2012**, 157, 1635-41	2.6	13
122	Development of a minigenome system for Andes virus, a New World hantavirus. *Archives of Virology* , **2012**, 157, 2227-33	2.6	11
121	The Syrian hamster model of hantavirus pulmonary syndrome. *Antiviral Research*, **2012**, 95, 282-92	10.8	49
120	Inclusion bodies are a site of ebolavirus replication. *Journal of Virology*, **2012**, 86, 11779-88	6.6	128
119	Enhanced detection of Rift Valley fever virus using molecular assays on whole blood samples. *Journal of Clinical Virology*, **2012**, 54, 313-7	14.5	9

118	Arenaviruses and filoviruses **2012**, 546-558		2
117	Current ebola vaccines. *Expert Opinion on Biological Therapy*, **2012**, 12, 859-72	5.4	63
116	Cathepsin B & L are not required for ebola virus replication. *PLoS Neglected Tropical Diseases*, **2012**, 6, e1923	4.8	52
115	The Ebola virus glycoprotein contributes to but is not sufficient for virulence in vivo. *PLoS Pathogens*, **2012**, 8, e1002847	7.6	74
114	Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever. *PLoS ONE*, **2012**, 7, e36192	3.7	110
113	A Hendra virus G glycoprotein subunit vaccine protects African green monkeys from Nipah virus challenge. *Science Translational Medicine*, **2012**, 4, 146ra107	17.5	91
112	Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates. *PLoS Neglected Tropical Diseases*, **2012**, 6, e1567	4.8	77
111	Ebola GP-specific monoclonal antibodies protect mice and guinea pigs from lethal Ebola virus infection. *PLoS Neglected Tropical Diseases*, **2012**, 6, e1575	4.8	77
110	Recently emerged swine influenza A virus (H2N3) causes severe pneumonia in Cynomolgus macaques. *PLoS ONE*, **2012**, 7, e39990	3.7	15
109	Ebola haemorrhagic fever. *Lancet, The*, **2011**, 377, 849-62	40	899
108	A replicating cytomegalovirus-based vaccine encoding a single Ebola virus nucleoprotein CTL epitope confers protection against Ebola virus. *PLoS Neglected Tropical Diseases*, **2011**, 5, e1275	4.8	68
107	In vitro and in vivo activity of ribavirin against Andes virus infection. *PLoS ONE*, **2011**, 6, e23560	3.7	45
106	Validation of assays to monitor immune responses in the Syrian golden hamster (Mesocricetus auratus). *Journal of Immunological Methods*, **2011**, 368, 24-35	2.5	72
105	Progress in filovirus vaccine development: evaluating the potential for clinical use. *Expert Review of Vaccines*, **2011**, 10, 63-77	5.2	81
104	Clinical aspects of Marburg hemorrhagic fever. *Future Virology*, **2011**, 6, 1091-1106	2.4	64
103	Genus-specific recruitment of filovirus ribonucleoprotein complexes into budding particles. *Journal of General Virology*, **2011**, 92, 2900-2905	4.9	18
102	A neutralizing human monoclonal antibody protects african green monkeys from hendra virus challenge. *Science Translational Medicine*, **2011**, 3, 105ra103	17.5	105
101	Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections. *Journal of Infectious Diseases*, **2011**, 204 Suppl 3, S1075-81	7	152

100	Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy. *Journal of Infectious Diseases*, **2011**, 204 Suppl 3, S1066-74	7	79
99	Clinical outcome of henipavirus infection in hamsters is determined by the route and dose of infection. *Journal of Virology*, **2011**, 85, 7658-71	6.6	87
98	Vesicular stomatitis virus-based vaccine protects hamsters against lethal challenge with Andes virus. *Journal of Virology*, **2011**, 85, 12781-91	6.6	58
97	Assessment of rodents as animal models for Reston ebolavirus. *Journal of Infectious Diseases*, **2011**, 204 Suppl 3, S968-72	7	21
96	Functional genomics reveals the induction of inflammatory response and metalloproteinase gene expression during lethal Ebola virus infection. *Journal of Virology*, **2011**, 85, 9060-8	6.6	32
95	Antibody-dependent enhancement of Marburg virus infection. *Journal of Infectious Diseases*, **2011**, 204 Suppl 3, S978-85	7	43
94	The Ebola virus glycoprotein and HIV-1 Vpu employ different strategies to counteract the antiviral factor tetherin. *Journal of Infectious Diseases*, **2011**, 204 Suppl 3, S850-60	7	56
93	Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany. *Journal of Infectious Diseases*, **2011**, 204 Suppl 3, S785-90	7	109
92	Pandemic swine-origin H1N1 influenza A virus isolates show heterogeneous virulence in macaques. *Journal of Virology*, **2011**, 85, 1214-23	6.6	79
91	Single immunization with a monovalent vesicular stomatitis virus-based vaccine protects nonhuman primates against heterologous challenge with Bundibugyo ebolavirus. *Journal of Infectious Diseases* , **2011**, 204 Suppl 3, S1082-9	7	44
90	A new Ebola virus nonstructural glycoprotein expressed through RNA editing. *Journal of Virology*, **2011**, 85, 5406-14	6.6	121
89	Pathogenesis and host response in Syrian hamsters following intranasal infection with Andes virus. *PLoS Pathogens*, **2011**, 7, e1002426	7.6	53
88	Host response dynamics following lethal infection of rhesus macaques with Zaire ebolavirus. *Journal of Infectious Diseases*, **2011**, 204 Suppl 3, S991-9	7	87
87	Protective efficacy of a bivalent recombinant vesicular stomatitis virus vaccine in the Syrian hamster model of lethal Ebola virus infection. *Journal of Infectious Diseases*, **2011**, 204 Suppl 3, S1090-7	7	42
86	Ebola virus enters host cells by macropinocytosis and clathrin-mediated endocytosis. *Journal of Infectious Diseases*, **2011**, 204 Suppl 3, S957-67	7	176
85	The Ebola virus soluble glycoprotein (sGP) does not affect lymphocyte apoptosis and adhesion to activated endothelium. *Journal of Infectious Diseases*, **2011**, 204 Suppl 3, S947-52	7	5
84	Ebola virion attachment and entry into human macrophages profoundly effects early cellular gene expression. *PLoS Neglected Tropical Diseases*, **2011**, 5, e1359	4.8	59
83	Nipah virus transmission in a hamster model. *PLoS Neglected Tropical Diseases*, **2011**, 5, e1432	4.8	43

82	The use of a mobile laboratory unit in support of patient management and epidemiological surveillance during the 2005 Marburg Outbreak in Angola. *PLoS Neglected Tropical Diseases*, **2011**, 5, e1183	4.8	46
81	Vesicular Stomatitis Virus-Based Vaccines for Prophylaxis and Treatment of Filovirus Infections. *Journal of Bioterrorism & Biodefense*, **2011**, S1,		40
80	Antagonism of type I interferon responses by new world hantaviruses. *Journal of Virology*, **2010**, 84, 11780-6801	6.6	46
79	Potent vesicular stomatitis virus-based avian influenza vaccines provide long-term sterilizing immunity against heterologous challenge. *Journal of Virology*, **2010**, 84, 4611-8	6.6	29
78	Oligomerization of Ebola virus VP40 is essential for particle morphogenesis and regulation of viral transcription. *Journal of Virology*, **2010**, 84, 7053-63	6.6	93
77	Enzyme-linked immunosorbent assay for detection of filovirus species-specific antibodies. *Vaccine Journal*, **2010**, 17, 1723-8		78
76	Preparing a community hospital to manage work-related exposures to infectious agents in BioSafety level 3 and 4 laboratories. *Emerging Infectious Diseases*, **2010**, 16, 373-8	10.2	18
75	Postexposure treatment of Marburg virus infection. *Emerging Infectious Diseases*, **2010**, 16, 1119-22	10.2	63
74	Detection of Lassa virus, Mali. *Emerging Infectious Diseases*, **2010**, 16, 1123-6	10.2	77
73	Are we any closer to combating Ebola infections?. *Lancet, The*, **2010**, 375, 1850-2	40	9
72	Prospects for immunisation against Marburg and Ebola viruses. *Reviews in Medical Virology*, **2010**, 20, 344-57	11.7	61
71	New World hantaviruses activate IFNlambda production in type I IFN-deficient vero E6 cells. *PLoS ONE*, **2010**, 5, e11159	3.7	37
70	Thoracic radiography as a refinement methodology for the study of H1N1 influenza in cynomologus macaques (Macaca fascicularis). *Comparative Medicine*, **2010**, 60, 389-95	1.6	46
69	Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses. *PLoS ONE*, **2009**, 4, e5547	3.7	110
68	Replication-deficient ebolavirus as a vaccine candidate. *Journal of Virology*, **2009**, 83, 3810-5	6.6	66
67	Chimeric human parainfluenza virus bearing the Ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against Ebola virus challenge. *Virology*, **2009**, 383, 348-61	3.6	51
66	Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus. *Journal of Virology*, **2009**, 83, 7296-304	6.6	202
65	The Ebola virus ribonucleoprotein complex: a novel VP30-L interaction identified. *Virus Research*, **2009**, 140, 8-14	6.4	69

64	Disease modeling for Ebola and Marburg viruses. *DMM Disease Models and Mechanisms*, **2009**, 2, 12-7	4.1	127
63	Responses to Ebola and Marburg Virus Infections **2009**, 371-390		
62	Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. *Vaccine*, **2008**, 26, 6894-900	4.1	147
61	Ebola virus matrix protein VP40 uses the COPII transport system for its intracellular transport. *Cell Host and Microbe*, **2008**, 3, 168-77	23.4	69
60	Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates. *Journal of Virology*, **2008**, 82, 5664-8	6.6	113
59	Stimulation of Ebola virus production from persistent infection through activation of the Ras/MAPK pathway. *Proceedings of the National Academy of Sciences of the United States of America* , **2008**, 105, 17982-7	11.5	64
58	Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. *PLoS Pathogens*, **2008**, 4, e1000225	7.6	155
57	Generation of biologically contained Ebola viruses. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 1129-33	11.5	84
56	Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice. *PLoS ONE*, **2008**, 3, e3548	3.7	125
55	Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever. *Journal of Infectious Diseases*, **2007**, 196 Suppl 2, S404-12	7	92
54	Person-to-person transmission of Nipah virus in a Bangladeshi community. *Emerging Infectious Diseases*, **2007**, 13, 1031-7	10.2	291
53	Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus. *Nature*, **2007**, 445, 319-23	50.4	762
52	Filoviruses: recent advances and future challenges. *Journal of Infectious Diseases*, **2007**, 196 Suppl 2, S129-30	7	8
51	Effective post-exposure treatment of Ebola infection. *PLoS Pathogens*, **2007**, 3, e2	7.6	212
50	In vitro evaluation of antisense RNA efficacy against filovirus infection, by use of reverse genetics. *Journal of Infectious Diseases*, **2007**, 196 Suppl 2, S382-9	7	13
49	In vitro and in vivo characterization of recombinant Ebola viruses expressing enhanced green fluorescent protein. *Journal of Infectious Diseases*, **2007**, 196 Suppl 2, S313-22	7	64
48	Dedication: Jim Orzechowski (1944–2003) and Michael Kiley (1942–2004). *Journal of Infectious Diseases*, **2007**, 196, S127-S128	7	1
47	Protective efficacy of neutralizing antibodies against Ebola virus infection. *Vaccine*, **2007**, 25, 993-9	4.1	77

46	The ecology of Ebola virus. *Trends in Microbiology*, **2007**, 15, 408-16	12.4	166
45	Cluster of Cases of Hantavirus Pulmonary Syndrome in Alberta, Canada. *American Journal of Tropical Medicine and Hygiene*, **2007**, 77, 914-918	3.2	9
44	Cluster of cases of hantavirus pulmonary syndrome in Alberta, Canada. *American Journal of Tropical Medicine and Hygiene*, **2007**, 77, 914-8	3.2	9
43	Marburg hemorrhagic fever--the forgotten cousin strikes. *New England Journal of Medicine*, **2006**, 355, 866-9	59.2	22
42	Molecular determinants of Ebola virus virulence in mice. *PLoS Pathogens*, **2006**, 2, e73	7.6	168
41	Assembly and budding of Ebolavirus. *PLoS Pathogens*, **2006**, 2, e99	7.6	126
40	Infection of naive target cells with virus-like particles: implications for the function of ebola virus VP24. *Journal of Virology*, **2006**, 80, 7260-4	6.6	103
39	Tyro3 family-mediated cell entry of Ebola and Marburg viruses. *Journal of Virology*, **2006**, 80, 10109-16	6.6	202
38	Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine. *Journal of Virology*, **2006**, 80, 9659-66	6.6	98
37	Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. *Lancet, The*, **2006**, 367, 1399-404	40	140
36	Ebola virus: unravelling pathogenesis to combat a deadly disease. *Trends in Molecular Medicine*, **2006**, 12, 206-15	11.5	130
35	Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. *Nature Medicine*, **2005**, 11, 786-90	50.5	506
34	Effects of Ebola virus glycoproteins on endothelial cell activation and barrier function. *Journal of Virology*, **2005**, 79, 10442-50	6.6	149
33	An animal model for the tickborne flavivirus--Omsk hemorrhagic fever virus. *Journal of Infectious Diseases*, **2005**, 191, 100-8	7	50
32	Development of a new vaccine for the prevention of Lassa fever. *PLoS Medicine*, **2005**, 2, e183	11.6	182
31	RNA polymerase I-driven minigenome system for Ebola viruses. *Journal of Virology*, **2005**, 79, 4425-33	6.6	66
30	Therapy and prophylaxis of Ebola virus infections. *Current Opinion in Investigational Drugs*, **2005**, 6, 823-30		24
29	Laboratory diagnosis of Ebola and Marburg hemorrhagic fever. *Bulletin De La Societe De Pathologie Exotique*, **2005**, 98, 205-9	0.4	54

28	Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. *Journal of Virology*, **2004**, 78, 5458-65	6.6	259
27	Enhanced virulence of influenza A viruses with the haemagglutinin of the 1918 pandemic virus. *Nature*, **2004**, 431, 703-7	50.4	374
26	Human macrophage C-type lectin specific for galactose and N-acetylgalactosamine promotes filovirus entry. *Journal of Virology*, **2004**, 78, 2943-7	6.6	206
25	Rescue of Ebola virus from cDNA using heterologous support proteins. *Virus Research*, **2004**, 106, 43-50	6.4	31
24	Ebola virus ecology: a continuing mystery. *Trends in Microbiology*, **2004**, 12, 433-7	12.4	48
23	Viral hemorrhagic fever □a vascular disease?. *Thrombosis and Haemostasis*, **2003**, 89, 967-972	7	150
22	Rescue of Hantaan virus minigenomes. *Virology*, **2003**, 306, 219-24	3.6	70
21	Ebola virus: from discovery to vaccine. *Nature Reviews Immunology*, **2003**, 3, 677-85	36.5	226
20	Identification of protective epitopes on ebola virus glycoprotein at the single amino acid level by using recombinant vesicular stomatitis viruses. *Journal of Virology*, **2003**, 77, 1069-74	6.6	93
19	Reverse genetics for crimean-congo hemorrhagic fever virus. *Journal of Virology*, **2003**, 77, 5997-6006	6.6	91
18	Reverse genetics demonstrates that proteolytic processing of the Ebola virus glycoprotein is not essential for replication in cell culture. *Journal of Virology*, **2002**, 76, 406-10	6.6	171
17	Molecular characterization of an isolate from the 1989/90 epizootic of Ebola virus Reston among macaques imported into the United States. *Virus Research*, **2002**, 87, 155-63	6.4	37
16	Infection and activation of monocytes by Marburg and Ebola viruses. *Journal of Virology*, **2001**, 75, 11025-33	6.6	181
15	Characterization of the L gene and 5□trailer region of Ebola virus. *Journal of General Virology*, **1999**, 80 (Pt 2), 355-362	4.9	92
14	Clinical, virologic, and immunologic follow-up of convalescent Ebola hemorrhagic fever patients and their household contacts, Kikwit, Democratic Republic of the Congo. Commission de Lutte contre les Epid□mies □Kikwit. *Journal of Infectious Diseases*, **1999**, 179 Suppl 1, S28-35	7	273
13	Release of viral glycoproteins during Ebola virus infection. *Virology*, **1998**, 245, 110-9	3.6	89
12	Marburg and Ebola hemorrhagic fevers: does the primary course of infection depend on the accessibility of organ-specific macrophages?. *Clinical Infectious Diseases*, **1998**, 27, 404-6	11.6	70
11	Processing of the Ebola virus glycoprotein by the proprotein convertase furin. *Proceedings of the National Academy of Sciences of the United States of America*, **1998**, 95, 5762-7	11.5	399

10	Filovirus-induced endothelial leakage triggered by infected monocytes/macrophages. *Journal of Virology*, **1996**, 70, 2208-14	6.6	192
9	Characterization of filoviruses based on differences in structure and antigenicity of the virion glycoprotein. *Virology*, **1994**, 199, 469-73	3.6	133
8	Genome structure and variability of a virus causing hantavirus pulmonary syndrome. *Virology*, **1994**, 200, 715-23	3.6	148
7	Genetic identification of a hantavirus associated with an outbreak of acute respiratory illness. *Science*, **1993**, 262, 914-7	33.3	846
6	Utilization of autopsy RNA for the synthesis of the nucleocapsid antigen of a newly recognized virus associated with hantavirus pulmonary syndrome. *Virus Research*, **1993**, 30, 351-67	6.4	156
5	Marburg virus, a filovirus: messenger RNAs, gene order, and regulatory elements of the replication cycle. *Virus Research*, **1992**, 24, 1-19	6.4	128
4	The nucleotide sequence of the L gene of Marburg virus, a filovirus: homologies with paramyxoviruses and rhabdoviruses. *Virology*, **1992**, 187, 534-47	3.6	68
3	Glycosylation and oligomerization of the spike protein of Marburg virus. *Virology*, **1991**, 182, 353-6	3.6	109
2	Hemorrhagic Fevers: Endothelial Cells and Ebola-Virus Hemorrhagic Fever1311-1319		1
1	Replicating RNA platform enables rapid response to the SARS-CoV-2 Omicron variant and elicits enhanced protection in naïve hamsters compared to ancestral vaccine		2